Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ziprasidone Clear all
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

NCT00257192
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, Ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
46
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

NCT00280566
View directory record Official record
Conditions
Bipolar Mania, Bipolar Disorder
Interventions
Placebo, Ziprasidone Oral Capsule
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
73
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 17, 2026, 2:59 AM EDT
Completed No phase listed Observational

Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

NCT03211897
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Haloperidol Injection, Ziprasidone Injection, OLANZapine Injection, Midazolam injection
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
737 participants
Timeline
2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Glucose and Lipid Metabolism on Antipsychotic Medication

NCT00515723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
risperidone, olanzapine, quetiapine, ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

NCT00288366
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 17, 2026, 2:59 AM EDT
Not listed No phase listed Observational

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

NCT00752960
View directory record Official record
Conditions
Psychoses
Interventions
Not listed
Lead sponsor
Genomas, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Hartford, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

The MIND Study: Modifying the INcidence of Delirium

NCT00096863
View directory record Official record
Conditions
Delirium, Cognition Disorders
Interventions
Ziprasidone, Haloperidol, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Iowa City, Iowa • Chapel Hill, North Carolina • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCT00338949
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

NCT00254202
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone, Ziprasidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

NCT00034801
View directory record Official record
Conditions
Depression, Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, ziprasidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
30
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 17, 2026, 2:59 AM EDT
Recruiting Phase 3 Interventional

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCT06482554
View directory record Official record
Conditions
Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions
Lumateperone 42 mg, Risperidone 2 mg
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

NCT00458211
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ziprasidone
Drug
Lead sponsor
Bronx Psychiatric Center
Government
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Buffalo, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

NCT00418171
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18,239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
San Bernardino, California • ‘Aiea, Hawaii • Schaumburg, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2009 · Synced Oct 17, 2026, 2:59 AM EDT
Terminated Phase 4 Interventional Results available

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

NCT00374543
View directory record Official record
Conditions
Generalized Anxiety Disorder, Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

NCT00257166
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone oral capsules, placebo oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
50
States / cities
Scottsdale, Arizona • Orange, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

NCT01172652
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Tampa, Florida • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

NCT01006551
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms

NCT00403546
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d
Drug
Lead sponsor
Donald C. Goff, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
9
States / cities
Augusta, Georgia • Fall River, Massachusetts • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

NCT00910988
View directory record Official record
Conditions
Hyperglycemia, Hyperlipidemia
Interventions
Olanzapine, Ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

NCT00634348
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
41
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

NCT01211522
View directory record Official record
Conditions
Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions
Haloperidol, Ziprasidone, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Ziprasidone in Children With Autism: A Pilot Study

NCT00208559
View directory record Official record
Conditions
Autism
Interventions
Ziprasidone
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 17, 2026, 2:59 AM EDT